Open access
Open access
Powered by Google Translator Translator

#ESCCongress | Study shows long-term Evolocumab appears to be safe in patients with established atherosclerotic cardiovascular disease.

30 Aug, 2022 | 12:12h | UTC

Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease – Circulation

News Release: Long-term evolocumab therapy leads to further reductions in cardiovascular events – European Society of Cardiology

Original Article: Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease – New England Journal of Medicine

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.